Evidence map›Paper›PMID 37452377›Full record

ArticleChemistry (Weinheim an der Bergstrasse, Germany)2023

Rapid Unambiguous Structure Elucidation of Streptnatamide A, a New Cyclic Peptide Isolated from A Marine-derived Streptomyces sp.

Jia-Xuan Yan, Qihao Wu, Mitasree Maity, Doug R Braun, Imraan Alas, Xiao Wang, Xing Yin, Yanlong Zhu, Bailey A Bell, Scott R Rajski and 4 more

Abstract read
In one paragraph

Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jia-Xuan YanMerck & Co., Inc., 126 E. Lincoln Ave, 07065, Rahway, NJ, USA.ORCID https://orcid.org/0000-0002-8432-3610
Qihao WuPharmaceutical Sciences Division, University of Wisconsin-Madison, 777 Highland Ave, 53705, Madison, WI, USA.
Mitasree MaityPharmaceutical Sciences Division, University of Wisconsin-Madison, 777 Highland Ave, 53705, Madison, WI, USA.
Doug R BraunPharmaceutical Sciences Division, University of Wisconsin-Madison, 777 Highland Ave, 53705, Madison, WI, USA.
Imraan AlasPharmaceutical Sciences Division, University of Wisconsin-Madison, 777 Highland Ave, 53705, Madison, WI, USA.
Xiao WangMerck & Co., Inc., 126 E. Lincoln Ave, 07065, Rahway, NJ, USA.
Xing YinMerck & Co., Inc., 126 E. Lincoln Ave, 07065, Rahway, NJ, USA.
Yanlong ZhuDepartment of Cell and Regenerative Biology, University of Wisconsin-Madison, 1111 Highland Ave, 53705, Madison, WI, USA.
Bailey A BellPharmaceutical Sciences Division, University of Wisconsin-Madison, 777 Highland Ave, 53705, Madison, WI, USA.
Scott R RajskiPharmaceutical Sciences Division, University of Wisconsin-Madison, 777 Highland Ave, 53705, Madison, WI, USA.
Ying GeDepartment of Cell and Regenerative Biology, University of Wisconsin-Madison, 1111 Highland Ave, 53705, Madison, WI, USA.
Douglas D RichardsonMerck & Co., Inc., 126 E. Lincoln Ave, 07065, Rahway, NJ, USA.
Wendy ZhongMerck & Co., Inc., 126 E. Lincoln Ave, 07065, Rahway, NJ, USA.
Tim S BugniPharmaceutical Sciences Division, University of Wisconsin-Madison, 777 Highland Ave, 53705, Madison, WI, USA.

Funding

Novel antimicrobials targeting MDR pathogens from animal microbial symbiontsU19AI142720 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI ANDES, DAVID R · 2019 to 2023
$30.1M
Metabolomics driven discovery of drug leads from symbiotic bacteriaU19AI109673 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI ANDES, DAVID R, CURRIE, CAMERON ROBERT · 2014 to 2018
$16.2M
TR&D 3: TECHNOLOGY DEVELOPMENT FOR NMR STUDIES OF SMALL MOLECULES (METABOLOMICS, NATURAL PRODUCTS, METABOLITE-PROTEIN INTERACTIONS) pp.537-585 P41GM103399 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI BUTCHER, SAMUEL E · 2012 to 2019
$9.4M
Technologies for Solid-State NMR Data CollectionP41GM136463 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI WESTLER, WILLIAM MILO · 2021 to 2025
$6.4M
NMR User Program at NMRFAMR24GM141526 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI Katherine Anne Henzler-Wildman · 2021 to 2026
$6.4M
Ultra High Resolution Mass Spectrometer for Biomedical ResearchS10OD018475 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI GE, YING · 2015 to 2015
$2.0M
NIAID NIH HHS U19 AI109673NIAID NIH HHS U19 AI142720NIGMS NIH HHS P41 GM103399NIGMS NIH HHS P41 GM136463NIGMS NIH HHS R24 GM141526NIH HHS S10 OD018475
6 · The paper itself

Abstract

Cyclic peptides have been excellent source of drug leads. With the advances in discovery platforms, the pharmaceutical industry has a growing interest in cyclic peptides and has pushed several into clinical trials. However, structural complexity of cyclic peptides brings extreme challenges for structure elucidation efforts. Isotopic fine structure analysis, Nuclear magnetic resonance (NMR), and detailed tandem mass spectrometry rapidly provided peptide sequence for streptnatamide A, a cyclic peptide isolated from a marine-derived Streptomyces sp. Marfey's analysis determined the stereochemistry of all amino acids, enabling the unambiguous structure determination of this compound. A non-ribosomal peptide synthetase biosynthetic gene cluster (stp) was tentatively identified and annotated for streptnatamide A based on the in silico analysis of whole genome sequencing data. These analytical tools will be powerful tools to overcome the challenges for cyclic peptide structure elucidation and accelerate the development of bioactive cyclic peptides.

Indexed as

Peptides, CyclicStreptomycesAmino AcidsAmino Acid SequenceTandem Mass SpectrometryAmino AcidsPeptides, Cycliccyclic peptidesisotopic fine structureNRPS biosynthesisstructure elucidationtandem mass spectrometry

Identifiers

PMID37452377
PMCPMC10592287

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.